Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1

por Lombaard, Johan, Ssali, Francis, Thanyawee, Puthanakit, Fourie, Jan, Vanveggel, Simon, Linthicum, Cornelia, Van Eygen, Veerle, Van Solingen-Ristea, Rodica
Publicado 2022

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin

por Fevery, Bart, Thys, Kim, Van Eygen, Veerle, Verbinnen, Thierry, Van Rossem, Elizabeth, Buelens, Annemie, Aerssens, Jeroen, Witek, James, Picchio, Gaston, De Meyer, Sandra, Lenz, Oliver
Publicado 2016

1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week...

por Talarico, Christine L, Wu, Sterling, Upadhyay, Ojesh R, Clair, Marty St, Van Eygen, Veerle, Hudson, Krischan J, Griffith, Sandy, Harrington, Conn M, van Lunzen, Jan, Margolis, David, Spreen, William
Publicado 2020

HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays

por Vandenbroucke, Ina, Van Marck, Herwig, Mostmans, Wendy, Van Eygen, Veerle, Rondelez, Evelien, Thys, Kim, Van Baelen, Kurt, Fransen, Katrien, Vaira, Dolores, Kabeya, Kabamba, De Wit, Stephane, Florence, Eric, Moutschen, Michel, Vandekerckhove, Linos, Verhofstede, Chris, Stuyver, Lieven J
Publicado 2010

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine

por Jeffrey, Jerry L., St. Clair, Marty, Wang, Ping, Wang, Chunfu, Li, Zhufang, Beloor, Jagadish, Talarico, Christine, Fridell, Robert, Krystal, Mark, White, C. Thomas, Griffith, Sandy, D’Amico, Ronald, Smith, Kimberly, Van Eygen, Veerle, Vingerhoets, Johan, Vandermeulen, Kati, Spreen, William, van Lunzen, Jan
Publicado 2022

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment

por Vandekerckhove, Linos, Verhofstede, Chris, Demecheleer, Els, De Wit, Stephane, Florence, Eric, Fransen, Katrien, Moutschen, Michel, Mostmans, Wendy, Kabeya, Kabamba, Mackie, Nicola, Plum, Jean, Vaira, Dolores, Van Baelen, Kurt, Vandenbroucke, Ina, Van Eygen, Veerle, Van Marck, Herwig, Vogelaers, Dirk, Geretti, Anna Maria, Stuyver, Lieven J
Publicado 2011

Observational cohort study of rilpivirine (RPV) utilization in Europe

por Cozzi-Lepri, Alessandro, Peters, Lars, Pelchen-Matthews, Annegret, Neesgaard, Bastian, De Wit, Stephane, Johansen, Isik Somuncu, Edwards, Simon, Stephan, Christoph, Adamis, Georgios, Staub, Therese, Zagalo, Alexandra, Domingo, Pere, Elbirt, Daniel, Kusejko, Katharina, Brännström, Johanna, Paduta, Dzmitry, Trofimova, Tatyana, Szlavik, Janos, Zilmer, Kai, Losso, Marcello, Van Eygen, Veerle, Pai, Helen, Lundgren, Jens, Mocroft, Amanda
Publicado 2022

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Lab...

por Overton, Edgar T, Richmond, Gary, Rizzardini, Giuliano, Thalme, Anders, Girard, Pierre-Marie, Wong, Alexander, Porteiro, Norma, Swindells, Susan, Reynes, Jacques, Noe, Sebastian, Harrington, Conn, Español, Carlos Martín, Acuipil, Carolina, Aksar, Asma, Wang, Yuanyuan, Ford, Susan L, Crauwels, Herta, van Eygen, Veerle, Van Solingen-Ristea, Rodica, Latham, Christine L, Thiagarajah, Shanker, D’Amico, Ronald, Smith, Kimberly Y, Vandermeulen, Kati, Spreen, William R
Publicado 2023

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, an...

por Orkin, Chloe, Schapiro, Jonathan M, Perno, Carlo F, Kuritzkes, Daniel R, Patel, Parul, DeMoor, Rebecca, Dorey, David, Wang, Yongwei, Han, Kelong, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L, Latham, Christine L, St. Clair, Marty, Polli, Joseph W, Vanveggel, Simon, Vandermeulen, Kati, D’Amico, Ronald, Garges, Harmony P, Zolopa, Andrew, Spreen, William R, van Wyk, Jean, Cutrell, Amy G
Publicado 2023

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

por Cutrell, Amy G., Schapiro, Jonathan M., Perno, Carlo F., Kuritzkes, Daniel R., Quercia, Romina, Patel, Parul, Polli, Joseph W., Dorey, David, Wang, Yongwei, Wu, Sterling, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L., Baker, Mark, Talarico, Christine L., Clair, Marty St, Jeffrey, Jerry, White, C. Thomas, Vanveggel, Simon, Vandermeulen, Kati, Margolis, David A., Aboud, Michael, Spreen, William R., van Lunzen, Jan
Publicado 2021

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

por Rizzardini, Giuliano, Overton, Edgar T., Orkin, Chloe, Swindells, Susan, Arasteh, Keikawus, Górgolas Hernández-Mora, Miguel, Pokrovsky, Vadim, Girard, Pierre-Marie, Oka, Shinichi, Andrade-Villanueva, Jaime F., Richmond, Gary J., Baumgarten, Axel, Masiá, Mar, Latiff, Gulam, Griffith, Sandy, Harrington, Conn M., Hudson, Krischan J., St. Clair, Marty, Talarico, Christine L., Patel, Parul, Cutrell, Amy, Van Eygen, Veerle, D'Amico, Ronald, Mrus, Joseph M., Wu, Sterling, Ford, Susan L., Chow, Ken, Roberts, Jeremy, Wills, Angela, Walters, Nicola, Vanveggel, Simon, Van Solingen-Ristea, Rodica, Crauwels, Herta, Smith, Kimberly Y., Spreen, William R., Margolis, David A.
Publicado 2020